WHO ICTRP trial
A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential…
NL-OMON36951 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON36951 |
|---|---|
| Public title | A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemia |
| Scientific title | A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemia - Vorinostat in PV and ET |
| Primary sponsor | Vrije Universiteit Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Denmark;Sweden;United Kingdom |
| Conditions | M. Vaquez-Osler myeloproliverative diseases;10018865;M. Vaquez-Osler;myeloproliverative diseases |
| Interventions | Caps. Vorinostat a 100 mg , 400 mg/day for a maximum of 6 months. Amendment 1: extended treatment for a year; if safe and effective it might be longer. ;essential thrombocythemia;polycythaemia vera;Vorinostat;Zolinza |
| Registration date | Mar 16, 2011 |
| Target size | 5 |
| Secondary IDs | 2007-005306-49;NCT00866762;NL27514.029.09 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: